The Treatment for Adolescents with Depression Study (TADS): Demographic and clinical characteristics

John March, Susan Silva*, Stephen Petrycki, John Curry, Karen Wells, John Fairbank, Barbara Burns, Marisa Domino, Steven McNulty, Benedetto Vitiello, Joanne Severe, Charles Casat, Jeanette Kolker, Karyn Riedal, Marguerita Goldman, Norah Feeny, Robert Findling, Sheridan Stull, Nora McNamara, Elizabeth WellerMichele Robins, Ronald Weller, Naushad Jessani, Bruce Waslick, Michael Sweeney, Rachel Kandel, Dena Schoenholz, John Walkup, Golda Ginsburg, Elizabeth Kastelic, Hyung Koo, Christopher Kratochvil, Diane May, Randy LaGrone, Martin Harrington, Anne Marie Albano, Glenn Hirsch, Tracey Knibbs, Emlyn Capili, Mark Reinecke, Bennett Leventhal, Catherine Nageotte, Gregory Rogers, Sanjeev Pathak, Jennifer Wells, Sarah Arszman, Arman Danielyan, Anne Simons, Paul Rohde, James Grimm

*Corresponding author for this work

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Objective: The Treatment for Adolescents With Depression Study is a multicenter, randomized clinical trial sponsored by the NIMH. This study is designed to evaluate the short- and long-term effectiveness of four treatments for adolescents with major depressive disorder: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. This report describes the demographic and clinical characteristics of the sample and addresses external validity. Method: Participants are 439 adolescents, aged 12-17 years inclusively, with a primary DSM-IV diagnosis of current major depressive disorder. Baseline data are summarized and compared with those from national samples and previous trials. Results: The sample composition is 54.4% girls, 73.8% white, 12.5% African American, and 8.9% Hispanic. The mean Child Depression Rating Scale-Revised total score is 60.1 (SD = 10.4, range 45-98) with 86.0% experiencing their first major depressive episode. The most common concurrent diagnoses are generalized anxiety disorder (15.3%), attention-deficit/hyperactivity disorder (13.7%), oppositional defiant disorder (13.2%), social phobia (10.7%), and dysthymia (10.5%). Demographic results are consistent with data from national samples and large psychopharmacology trials involving depressed adolescents. Conclusions: The Treatment for Adolescents With Depression Study provides a large, diverse, and representative sample of depressed adolescents that highlights the complexity of major depressive disorder in adolescents and provides a rich source for explicating the effects of moderator and mediator variables on baseline psychopathology and treatment outcome.

Original languageEnglish (US)
Pages (from-to)28-40
Number of pages13
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2005

Fingerprint

Demography
Depression
Major Depressive Disorder
Therapeutics
Epidemiologic Effect Modifiers
Attention Deficit and Disruptive Behavior Disorders
National Institute of Mental Health (U.S.)
Psychopharmacology
Fluoxetine
Cognitive Therapy
Attention Deficit Disorder with Hyperactivity
Clinical Studies
Anxiety Disorders
Psychopathology
Hispanic Americans
Diagnostic and Statistical Manual of Mental Disorders
African Americans
Randomized Controlled Trials
Placebos

Keywords

  • Adolescence
  • Controlled trials
  • Depression
  • Phenomenology
  • Randomized
  • Treatment

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

March, John ; Silva, Susan ; Petrycki, Stephen ; Curry, John ; Wells, Karen ; Fairbank, John ; Burns, Barbara ; Domino, Marisa ; McNulty, Steven ; Vitiello, Benedetto ; Severe, Joanne ; Casat, Charles ; Kolker, Jeanette ; Riedal, Karyn ; Goldman, Marguerita ; Feeny, Norah ; Findling, Robert ; Stull, Sheridan ; McNamara, Nora ; Weller, Elizabeth ; Robins, Michele ; Weller, Ronald ; Jessani, Naushad ; Waslick, Bruce ; Sweeney, Michael ; Kandel, Rachel ; Schoenholz, Dena ; Walkup, John ; Ginsburg, Golda ; Kastelic, Elizabeth ; Koo, Hyung ; Kratochvil, Christopher ; May, Diane ; LaGrone, Randy ; Harrington, Martin ; Albano, Anne Marie ; Hirsch, Glenn ; Knibbs, Tracey ; Capili, Emlyn ; Reinecke, Mark ; Leventhal, Bennett ; Nageotte, Catherine ; Rogers, Gregory ; Pathak, Sanjeev ; Wells, Jennifer ; Arszman, Sarah ; Danielyan, Arman ; Simons, Anne ; Rohde, Paul ; Grimm, James. / The Treatment for Adolescents with Depression Study (TADS) : Demographic and clinical characteristics. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2005 ; Vol. 44, No. 1. pp. 28-40.
@article{3909010d7ed241918d742cc525b94570,
title = "The Treatment for Adolescents with Depression Study (TADS): Demographic and clinical characteristics",
abstract = "Objective: The Treatment for Adolescents With Depression Study is a multicenter, randomized clinical trial sponsored by the NIMH. This study is designed to evaluate the short- and long-term effectiveness of four treatments for adolescents with major depressive disorder: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. This report describes the demographic and clinical characteristics of the sample and addresses external validity. Method: Participants are 439 adolescents, aged 12-17 years inclusively, with a primary DSM-IV diagnosis of current major depressive disorder. Baseline data are summarized and compared with those from national samples and previous trials. Results: The sample composition is 54.4{\%} girls, 73.8{\%} white, 12.5{\%} African American, and 8.9{\%} Hispanic. The mean Child Depression Rating Scale-Revised total score is 60.1 (SD = 10.4, range 45-98) with 86.0{\%} experiencing their first major depressive episode. The most common concurrent diagnoses are generalized anxiety disorder (15.3{\%}), attention-deficit/hyperactivity disorder (13.7{\%}), oppositional defiant disorder (13.2{\%}), social phobia (10.7{\%}), and dysthymia (10.5{\%}). Demographic results are consistent with data from national samples and large psychopharmacology trials involving depressed adolescents. Conclusions: The Treatment for Adolescents With Depression Study provides a large, diverse, and representative sample of depressed adolescents that highlights the complexity of major depressive disorder in adolescents and provides a rich source for explicating the effects of moderator and mediator variables on baseline psychopathology and treatment outcome.",
keywords = "Adolescence, Controlled trials, Depression, Phenomenology, Randomized, Treatment",
author = "John March and Susan Silva and Stephen Petrycki and John Curry and Karen Wells and John Fairbank and Barbara Burns and Marisa Domino and Steven McNulty and Benedetto Vitiello and Joanne Severe and Charles Casat and Jeanette Kolker and Karyn Riedal and Marguerita Goldman and Norah Feeny and Robert Findling and Sheridan Stull and Nora McNamara and Elizabeth Weller and Michele Robins and Ronald Weller and Naushad Jessani and Bruce Waslick and Michael Sweeney and Rachel Kandel and Dena Schoenholz and John Walkup and Golda Ginsburg and Elizabeth Kastelic and Hyung Koo and Christopher Kratochvil and Diane May and Randy LaGrone and Martin Harrington and Albano, {Anne Marie} and Glenn Hirsch and Tracey Knibbs and Emlyn Capili and Mark Reinecke and Bennett Leventhal and Catherine Nageotte and Gregory Rogers and Sanjeev Pathak and Jennifer Wells and Sarah Arszman and Arman Danielyan and Anne Simons and Paul Rohde and James Grimm",
year = "2005",
month = "1",
day = "1",
doi = "10.1097/01.chi.0000145807.09027.82",
language = "English (US)",
volume = "44",
pages = "28--40",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "1",

}

March, J, Silva, S, Petrycki, S, Curry, J, Wells, K, Fairbank, J, Burns, B, Domino, M, McNulty, S, Vitiello, B, Severe, J, Casat, C, Kolker, J, Riedal, K, Goldman, M, Feeny, N, Findling, R, Stull, S, McNamara, N, Weller, E, Robins, M, Weller, R, Jessani, N, Waslick, B, Sweeney, M, Kandel, R, Schoenholz, D, Walkup, J, Ginsburg, G, Kastelic, E, Koo, H, Kratochvil, C, May, D, LaGrone, R, Harrington, M, Albano, AM, Hirsch, G, Knibbs, T, Capili, E, Reinecke, M, Leventhal, B, Nageotte, C, Rogers, G, Pathak, S, Wells, J, Arszman, S, Danielyan, A, Simons, A, Rohde, P & Grimm, J 2005, 'The Treatment for Adolescents with Depression Study (TADS): Demographic and clinical characteristics', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 44, no. 1, pp. 28-40. https://doi.org/10.1097/01.chi.0000145807.09027.82

The Treatment for Adolescents with Depression Study (TADS) : Demographic and clinical characteristics. / March, John; Silva, Susan; Petrycki, Stephen; Curry, John; Wells, Karen; Fairbank, John; Burns, Barbara; Domino, Marisa; McNulty, Steven; Vitiello, Benedetto; Severe, Joanne; Casat, Charles; Kolker, Jeanette; Riedal, Karyn; Goldman, Marguerita; Feeny, Norah; Findling, Robert; Stull, Sheridan; McNamara, Nora; Weller, Elizabeth; Robins, Michele; Weller, Ronald; Jessani, Naushad; Waslick, Bruce; Sweeney, Michael; Kandel, Rachel; Schoenholz, Dena; Walkup, John; Ginsburg, Golda; Kastelic, Elizabeth; Koo, Hyung; Kratochvil, Christopher; May, Diane; LaGrone, Randy; Harrington, Martin; Albano, Anne Marie; Hirsch, Glenn; Knibbs, Tracey; Capili, Emlyn; Reinecke, Mark; Leventhal, Bennett; Nageotte, Catherine; Rogers, Gregory; Pathak, Sanjeev; Wells, Jennifer; Arszman, Sarah; Danielyan, Arman; Simons, Anne; Rohde, Paul; Grimm, James.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 44, No. 1, 01.01.2005, p. 28-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Treatment for Adolescents with Depression Study (TADS)

T2 - Demographic and clinical characteristics

AU - March, John

AU - Silva, Susan

AU - Petrycki, Stephen

AU - Curry, John

AU - Wells, Karen

AU - Fairbank, John

AU - Burns, Barbara

AU - Domino, Marisa

AU - McNulty, Steven

AU - Vitiello, Benedetto

AU - Severe, Joanne

AU - Casat, Charles

AU - Kolker, Jeanette

AU - Riedal, Karyn

AU - Goldman, Marguerita

AU - Feeny, Norah

AU - Findling, Robert

AU - Stull, Sheridan

AU - McNamara, Nora

AU - Weller, Elizabeth

AU - Robins, Michele

AU - Weller, Ronald

AU - Jessani, Naushad

AU - Waslick, Bruce

AU - Sweeney, Michael

AU - Kandel, Rachel

AU - Schoenholz, Dena

AU - Walkup, John

AU - Ginsburg, Golda

AU - Kastelic, Elizabeth

AU - Koo, Hyung

AU - Kratochvil, Christopher

AU - May, Diane

AU - LaGrone, Randy

AU - Harrington, Martin

AU - Albano, Anne Marie

AU - Hirsch, Glenn

AU - Knibbs, Tracey

AU - Capili, Emlyn

AU - Reinecke, Mark

AU - Leventhal, Bennett

AU - Nageotte, Catherine

AU - Rogers, Gregory

AU - Pathak, Sanjeev

AU - Wells, Jennifer

AU - Arszman, Sarah

AU - Danielyan, Arman

AU - Simons, Anne

AU - Rohde, Paul

AU - Grimm, James

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: The Treatment for Adolescents With Depression Study is a multicenter, randomized clinical trial sponsored by the NIMH. This study is designed to evaluate the short- and long-term effectiveness of four treatments for adolescents with major depressive disorder: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. This report describes the demographic and clinical characteristics of the sample and addresses external validity. Method: Participants are 439 adolescents, aged 12-17 years inclusively, with a primary DSM-IV diagnosis of current major depressive disorder. Baseline data are summarized and compared with those from national samples and previous trials. Results: The sample composition is 54.4% girls, 73.8% white, 12.5% African American, and 8.9% Hispanic. The mean Child Depression Rating Scale-Revised total score is 60.1 (SD = 10.4, range 45-98) with 86.0% experiencing their first major depressive episode. The most common concurrent diagnoses are generalized anxiety disorder (15.3%), attention-deficit/hyperactivity disorder (13.7%), oppositional defiant disorder (13.2%), social phobia (10.7%), and dysthymia (10.5%). Demographic results are consistent with data from national samples and large psychopharmacology trials involving depressed adolescents. Conclusions: The Treatment for Adolescents With Depression Study provides a large, diverse, and representative sample of depressed adolescents that highlights the complexity of major depressive disorder in adolescents and provides a rich source for explicating the effects of moderator and mediator variables on baseline psychopathology and treatment outcome.

AB - Objective: The Treatment for Adolescents With Depression Study is a multicenter, randomized clinical trial sponsored by the NIMH. This study is designed to evaluate the short- and long-term effectiveness of four treatments for adolescents with major depressive disorder: fluoxetine, cognitive-behavioral therapy, their combination, and, acutely, pill placebo. This report describes the demographic and clinical characteristics of the sample and addresses external validity. Method: Participants are 439 adolescents, aged 12-17 years inclusively, with a primary DSM-IV diagnosis of current major depressive disorder. Baseline data are summarized and compared with those from national samples and previous trials. Results: The sample composition is 54.4% girls, 73.8% white, 12.5% African American, and 8.9% Hispanic. The mean Child Depression Rating Scale-Revised total score is 60.1 (SD = 10.4, range 45-98) with 86.0% experiencing their first major depressive episode. The most common concurrent diagnoses are generalized anxiety disorder (15.3%), attention-deficit/hyperactivity disorder (13.7%), oppositional defiant disorder (13.2%), social phobia (10.7%), and dysthymia (10.5%). Demographic results are consistent with data from national samples and large psychopharmacology trials involving depressed adolescents. Conclusions: The Treatment for Adolescents With Depression Study provides a large, diverse, and representative sample of depressed adolescents that highlights the complexity of major depressive disorder in adolescents and provides a rich source for explicating the effects of moderator and mediator variables on baseline psychopathology and treatment outcome.

KW - Adolescence

KW - Controlled trials

KW - Depression

KW - Phenomenology

KW - Randomized

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=19944363159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944363159&partnerID=8YFLogxK

U2 - 10.1097/01.chi.0000145807.09027.82

DO - 10.1097/01.chi.0000145807.09027.82

M3 - Article

C2 - 15608541

AN - SCOPUS:19944363159

VL - 44

SP - 28

EP - 40

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 1

ER -